Edition:
United Kingdom

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

8.61USD
9:00pm BST
Change (% chg)

$-0.11 (-1.26%)
Prev Close
$8.72
Open
$8.72
Day's High
$8.80
Day's Low
$8.59
Volume
153,389
Avg. Vol
171,054
52-wk High
$18.78
52-wk Low
$7.34

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics Says Co Entered First Amendment To Agreement & Plan Of Merger With Alpha Therapeutics, Co's Unit And Keryx
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS SAYS CO ENTERED FIRST AMENDMENT TO AGREEMENT & PLAN OF MERGER WITH ALPHA THERAPEUTICS, CO'S UNIT AND KERYX - SEC FILING.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER CO MUST CAUSE INCREASE IN SIZE OF THE AKEBIA BOARD TO 10 DIRECTORS.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER ADDITIONAL DIRECTOR SHALL SERVE AS CHAIRPERSON OF AKEBIA BOARD.  Full Article

Nantahala Capital Management Reports 9.8 Pct Stake In Akebia Therapeutics
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Nantahala Capital Management Llc::NANTAHALA CAPITAL MANAGEMENT LLC REPORTS 9.8 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF SEPTEMBER 25 - SEC FILING.NANTAHALA CAPITAL MANAGEMENT LLC PURCHASED AKEBIA THERAPEUTICS COMMON STOCK BASED ON BELIEF THAT COMMON STOCK, WHEN PURCHASED, WAS UNDERVALUED.  Full Article

Akebia Therapeutics Q2 Loss Per Share $0.60
Wednesday, 8 Aug 2018 

Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.60.Q2 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.QUARTERLY COLLABORATION REVENUE $48.8 MILLION VERSUS $28.5 MILLION.  Full Article

Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE.DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​.‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​.STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​.STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​.SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES.NO DEATHS WERE REPORTED.  Full Article

Akebia Therapeutics reports Q3 loss per share $0.49
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article

Akebia Therapeutics provides update on Janssen deal
Monday, 13 Feb 2017 

Akebia Therapeutics Inc : Akebia Therapeutics - Janssen could be eligible to receive up to aggregate of $16.5 million from co in specified development milestone payments . Akebia Therapeutics - Janssen to be eligible to receive up to $215 million from co in specified commercial milestones as well as tiered, escalating royalties . Akebia Therapeutics - unless earlier terminated, deal will expire on a product-by-product and country-by-country basis upon expiration of last royalty term .Akebia Therapeutics-co may terminate deal in its entirety or only with respect to particular licensed compound upon 180 days' prior written notice to Janssen.  Full Article

Akebia to pay Janssen to access come intellectual property
Monday, 13 Feb 2017 

Akebia Therapeutics Inc - : Will pay Janssen $1.0 million in cash to access their collection of hundreds of HIF-targeted compounds, associated intellectual property . Co obtains worldwide rights to akb-5169, a non-absorbed oral HIF stabilizer in preclinical development for treatment of IBD . Johnson & Johnson innovation has opportunity to take ownership interest in co through common stock purchase warrant issued by co to JJDC . JJDC can take ownership interest in co through common stock purchase warrant issued by co to JJDC for 509,611 shares of co's common stock .Warrant exercisable by JJDC, in whole or in part, at any time prior to 5th anniversary of date of issuance with payment to co of up to $5 million.  Full Article

UPDATE 2-Ex-biopharmaceutical employees convicted in U.S. of insider trading

BOSTON, July 10 Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading.